ArticleDrug delivery2021
Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment.
Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- Nanomedicines and stroke: Advantages in chronic inflammation treatment and neural regeneration.Neural regeneration research · 2026Article
- Synthesis and performance optimization of multi-bioactive compound-loaded nanocarriers for antimicrobial applications.Scientific reports · 2025Article
- Biomaterials for CNS disorders: a review of development from traditional methods to AI-assisted optimization.Journal of materials science. Materials in medicine · 2025Review
- ADME analysis, metabolic prediction, and molecular docking of lipoic acid with SARS-CoV-2 Omicron spike protein.Scientific reports · 2025Article
- Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.Materials today. Bio · 2025Review
- Article
- Revolutionizing Stroke Care: Nanotechnology-Based Brain Delivery as a Novel Paradigm for Treatment and Diagnosis.Molecular neurobiology · 2025Review
- Current Status of Research on Nanomaterials Combined with Mesenchymal Stem Cells for the Treatment of Ischemic Stroke.Neuromolecular medicine · 2024Review
- State of the Art in the Development of Human Serum Carnosinase Inhibitors.Molecules (Basel, Switzerland) · 2024Review
- Advanced Nano-Drug Delivery Systems in the Treatment of Ischemic Stroke.Molecules (Basel, Switzerland) · 2024Review
- Multiscale physics-basedFrontiers in drug delivery · 2024Review
- Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds.EXCLI journal · 2024Review
- Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases.Drug delivery · 2023Review
- Nanomaterial-Based Drug Delivery Systems for Ischemic Stroke.Pharmaceutics · 2023Review
- Nanoparticle Formulations of Antioxidants for the Management of Oxidative Stress in Stroke: A Review.Biomedicines · 2023Review
- Recent Advances in Nanotherapeutics for Neurological Disorders.ACS applied bio materials · 2023Review
- Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives.Pharmaceutics · 2023Review
- The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Nanotechnology in Stroke: New Trails with Smaller Scales.Biomedicines · 2023Review
- Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer's Disease.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of suitable drug delivery carriers is significant in biomedical applications to improve the therapeutic efficiency. Recent progress in nanotechnological fields, paved the way for the formulation of variety of drug carriers. The brain disorders such as ischemic stroke, brain cancer, and CNS disorders were poorly treated due to the presence of blood brain barrier that hinders the passage of drugs to the brain. Hence, the formulated drugs should have the ability to cross the blood-brain barrier (BBB) for ischemic stroke treatment. In the present work, we have synthesized PLGA functionalized magnetic Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.